Also, the targeting system, although giving high tumour to blood ratios of antibody-enzyme conjugate (10 000 : 1), was complicated, requiring additional administration of a mouse monoclonal clearing antibody directed to the active site of CPG2 (Napier et al, 2000). The gene discussed is SYNE1; the disease is neoplasm.